Sage Therapeutics shares soar after postpartum drug meets main goal

Sage Therapeutics said Thursday its drug to treat moderate in addition to severe postpartum depression met the main goal in two late-stage studies.

The stock soared as much as 50 percent in premarket on Thursday.

The drug, brexanolone, achieved lower rates of depression in patients compared which has a placebo in both trials.

Postpartum depression will be a common complication of childbirth of which affects about 10 to 20 percent of women giving birth within the United States, the company said.

—CNBC’s Berkeley Lovelace Jr. contributed to This particular report.

Leave a Reply

Your email address will not be published. Required fields are marked *


fourteen − 9 =